Our CEO and co-founder, Choon-Peng (Choon) Ng recently spoke with BioSpectrum Asia about how our unique Deep Immunomics and machine learning platforms can discover and develop novel TCR-based therapeutics against a diverse range of tumor antigens. You can see the full feature at the link below.
Nextgen TCR therapies can improve diagnosis and treatment regimens
January 19, 2023